Javascript must be enabled to continue!
A Model-Based Concurrent Specification Language over CML: Semantic Foundations
View through CrossRef
In this paper we address the problem of specification and design of concurrent systems. More accurately, we present the definition of a new specification language that is formal, wide-spectrum, model-based, concurrent, polymorphic and strongly implicitly typed. The language is built upon a concurrent, funtional and imperative programming language: Concurrent ML. Specification aspects are supported thanks to the addition of some specification constructs and also by allowing axioms to ML structures and signatures. The resulting specification language is thus highly expressive though it embodies a restricted number of concepts. We present here the motivations underlying the definition of such a language as well as the design choices. Furthermore, we introduce the specification and development methology and illustrate it on various examples. We will see that many specification styles are allowed: algebraic, applicative, state-based, concurrent applicative and concurrent imperative. We show that the language rests on secure theoretical foundations exemplified by formal syntactic and semantic definitions. The latter consists in a static semantics together with a dynamic semantics. The static semantics reconstructs not only principal types but also minimal side and communication effects. This is done thanks to an extension of the type and effect discipline. The language is also endowed with a dynamic denotational semantics. The underlying model is based on an extension of the acceptance trees model to handle value-passing, communication, assignment, sequencing, return of results and higher order objects.
Title: A Model-Based Concurrent Specification Language over CML: Semantic Foundations
Description:
In this paper we address the problem of specification and design of concurrent systems.
More accurately, we present the definition of a new specification language that is formal, wide-spectrum, model-based, concurrent, polymorphic and strongly implicitly typed.
The language is built upon a concurrent, funtional and imperative programming language: Concurrent ML.
Specification aspects are supported thanks to the addition of some specification constructs and also by allowing axioms to ML structures and signatures.
The resulting specification language is thus highly expressive though it embodies a restricted number of concepts.
We present here the motivations underlying the definition of such a language as well as the design choices.
Furthermore, we introduce the specification and development methology and illustrate it on various examples.
We will see that many specification styles are allowed: algebraic, applicative, state-based, concurrent applicative and concurrent imperative.
We show that the language rests on secure theoretical foundations exemplified by formal syntactic and semantic definitions.
The latter consists in a static semantics together with a dynamic semantics.
The static semantics reconstructs not only principal types but also minimal side and communication effects.
This is done thanks to an extension of the type and effect discipline.
The language is also endowed with a dynamic denotational semantics.
The underlying model is based on an extension of the acceptance trees model to handle value-passing, communication, assignment, sequencing, return of results and higher order objects.
Related Results
Hubungan Perilaku Pola Makan dengan Kejadian Anak Obesitas
Hubungan Perilaku Pola Makan dengan Kejadian Anak Obesitas
<p><em><span style="font-size: 11.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-langua...
Safety and Efficacy of Tgrx-678, a Potent BCR-ABL Allosteric Inhibitor in Patients with Tyrosine Kinase Inhibitor (TKI) Resistant/Refractory Chronic Myeloid Leukemia (CML): Preliminary Results of Phase I Study
Safety and Efficacy of Tgrx-678, a Potent BCR-ABL Allosteric Inhibitor in Patients with Tyrosine Kinase Inhibitor (TKI) Resistant/Refractory Chronic Myeloid Leukemia (CML): Preliminary Results of Phase I Study
Background:
TGRX-678 is a novel allosteric inhibitor of ABL kinases, specifically targeting the ABL Myristoyl Pocket (STAMP). In vitro data supports TGRX-678 targeti...
Characteristics of regional epidemiological indicators of chronic myeloproliferative neoplasms
Characteristics of regional epidemiological indicators of chronic myeloproliferative neoplasms
Background. Information on the epidemiological picture of chronic myeloid leukemia (CML) and, especially, Ph– chronic myeloproliferative neoplasm (MPN) in Russia is very scarce, ea...
Preferentially expressed genes in chronic myelogenous leukemia
Preferentially expressed genes in chronic myelogenous leukemia
Abstract
The predominant circulating cells in chronic myelogenous leukemia (CML) morphologically resemble normal myeloid precursors; however, certain characteristics...
CAR-macrophages targets CD26 to eliminate chronic myeloid leukemia stem cells
CAR-macrophages targets CD26 to eliminate chronic myeloid leukemia stem cells
Abstract
Background
Chronic myeloid leukemia stem cells (CML-LSCs), which exhibit resistance to tyrosine kinase inhibitors (TKIs), are the leadin...
Targeting of plasminogen activator inhibitor-1 activity promotes elimination of chronic myeloid leukemia stem cells
Targeting of plasminogen activator inhibitor-1 activity promotes elimination of chronic myeloid leukemia stem cells
Therapeutic strategies that target leukemic stem cells (LSCs) provide potential advantages in the treatment of chronic myeloid leukemia (CML). Here, we show that selective blockade...
Detection of Compound BCR-ABL Mutations in TKI Resistant CML Patients Including a Novel K245N Mutation Associated with Primary Nilotinib Resistance By Employing a Newly Developed Cost Effective BCR-ABL Sequencing Protocol
Detection of Compound BCR-ABL Mutations in TKI Resistant CML Patients Including a Novel K245N Mutation Associated with Primary Nilotinib Resistance By Employing a Newly Developed Cost Effective BCR-ABL Sequencing Protocol
Abstract
Introduction: BCR-ABL mutations are the major background players in manifestation of resistance to all FDA approved tyrosine kinase inhibitors (TKIs) includ...
TRIM28 Facilitates Chronic Myeloid Leukemia Progression By Enhancing Sumoylation and Stability of BCR-ABL
TRIM28 Facilitates Chronic Myeloid Leukemia Progression By Enhancing Sumoylation and Stability of BCR-ABL
Chronic myeloid leukemia (CML) is a hematopoietic malignancy caused by the BCR-ABL fusion gene. Although tyrosine kinase inhibitors (TKIs) targeting the oncoprotein BCR-ABL have dr...

